featured
HR-QoL With First-Line Eribulin ± Trastuzumab for Locally Recurrent or Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
BMC Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Health-Related Quality of Life in Patients Receiving First-Line Eribulin Mesylate With or Without Trastuzumab for Locally Recurrent or Metastatic Breast Cancer
BMC Cancer 2019 Jun 13;19(1)578, L Schwartzberg, K McIntyre, S Wilks, S Puhalla, J O'Shaughnessy, E Berrak, Y He, L VahdatFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.